MaxCyte IPO Presentation Deck

2020 2019 2018 2017 2016 2015 Solid 5-year Financial Results 2015-2020 July 2021 Revenue (USD, 000s) 5 Year Revenue CAGR 23% $12,270 $9,290 $16,667 $13,985 $21,620 $26,169 2020 2019 2018 2017 2016 2015 Instruments Placed Rapid Growth of Licensed Placements Gross Margin Pharmaceutical-level Margins ~89% 2015-2020 160 125 + 250+ 200 + 320 + 400 + CONFIDENTIAL Recurring Revenue Average total expected annual revenue from leased instruments and consumabie sales as of 12/31/2015-2020 as % of TTM revenue 2020 2019 2018 2017 2016 2015 Recurring Revenues (% of TTM revenues) 72% Partnered Programs Rapid Growth of Licensed Programs Licensed Clinical Programs M MaxCyte 28% Partnered Programs *Excluding deals signed before 2015 Total Commercial Licenses 12** 8 3 1 0 "3 partnerships signed in 2020 and 1 in early Jan, 2021 15

View entire presentation